CUROSURF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CUROSURF (CUROSURF).
CUROSURF is a natural porcine lung surfactant containing phospholipids and surfactant-associated proteins B and C. It reduces surface tension in the alveoli, preventing alveolar collapse at end-expiration and improving lung compliance and gas exchange.
| Metabolism | CUROSURF is not metabolized; it acts locally in the lungs and is cleared by alveolar macrophages and reabsorption into lung tissue. |
| Excretion | The primary route of elimination is via alveolar macrophages and clearance from the lungs; renal and biliary excretion are negligible as the drug is a surfactant administered directly to the lungs. |
| Half-life | The terminal elimination half-life is approximately 24-48 hours in preterm infants, reflecting slow clearance from the lungs; clinical effects on lung function can be seen within minutes. |
| Protein binding | Not applicable (Curosurf is a surfactant and does not bind to plasma proteins; it acts locally in the lungs). |
| Volume of Distribution | Not applicable; Curosurf is administered directly to the lungs and remains primarily in the pulmonary space; systemic distribution is minimal. |
| Bioavailability | Bioavailability is 100% via intratracheal administration as it is delivered directly to the site of action. |
| Onset of Action | Onset of action occurs within minutes after intratracheal administration, with improvement in oxygenation and lung compliance observed shortly after dosing. |
| Duration of Action | Duration of effect is typically 24-48 hours, with some infants requiring repeat doses; clinical improvement in respiratory function is sustained for the duration of surfactant activity. |
| Action Class | Pulmonary Surfactant |
Curosurf is administered intratracheally as a single dose of 100-200 mg/kg (1.25-2.5 mL/kg) of birth weight, given as soon as possible after birth. Repeat doses of 100 mg/kg (1.25 mL/kg) may be given at 12-hour intervals up to a total of 3 doses if needed.
| Dosage form | SUSPENSION |
| Renal impairment | No dose adjustment required for renal impairment; Curosurf is not systemically absorbed and acts locally in the lungs. |
| Liver impairment | No dose adjustment required for hepatic impairment; Curosurf is not metabolized by the liver and acts locally. |
| Pediatric use | For premature infants (less than 32 weeks gestational age) with respiratory distress syndrome (RDS): initial dose 100-200 mg/kg intratracheally; repeat doses of 100 mg/kg every 12 hours up to 3 total doses if respiratory status worsens. |
| Geriatric use | Curosurf is not indicated for geriatric patients; it is used exclusively in neonatal respiratory distress syndrome. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CUROSURF (CUROSURF).
| Breastfeeding | Curosurf is not absorbed systemically after tracheal administration; it is not excreted into breast milk. Breastfeeding is not contraindicated. M/P ratio is not applicable. |
| Teratogenic Risk | Curosurf (poractant alfa) is administered directly to the neonatal respiratory tract; no fetal exposure occurs in utero. No teratogenic risk applies. |
| Fetal Monitoring | Not applicable for maternal administration. For neonatal use, monitor: oxygen saturation, heart rate, respiratory rate, blood gases, and lung compliance during and after administration. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to porcine proteins or any component of the formulation","Absolute contraindication: none known"]
| Precautions | ["Rapid administration may cause airway obstruction, bradycardia, and hypotension","Monitor oxygen saturation, heart rate, and blood pressure during administration","Use sterile techniques to avoid contamination","Potential for pulmonary hemorrhage in extremely premature infants"] |
Loading safety data…
| Fertility Effects | No known impact on fertility. Curosurf is not administered to women of reproductive age for systemic effects. |